GlobeNewswire

Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings

Share
  • High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1
  • Once-daily Enerzair Breezhaler, which includes an optional digital companion (sensor and app), is the first LABA/LAMA/ICS* fixed-dose combination approved for patients whose asthma is uncontrolled with a LABA/ICS2
  • Post hoc analysis complements findings from pivotal Phase III IRIDIUM study recently published in The Lancet Respiratory Medicine3

Basel, September 7, 2020 — Novartis today announced that high-dose, once-daily Enerzair® Breezhaler® (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) significantly reduces both moderate-or-severe and severe asthma exacerbation rates in patients whose asthma is uncontrolled on medium- or high-dose long-acting beta2-agonist (LABA)/inhaled corticosteroids (ICS), when compared with a once-daily medium-dose of the same treatment. The post hoc analysis from the pivotal Phase III IRIDIUM study—presented virtually at the European Respiratory Society (ERS) International Congress 2020— also showed the safety profile for high-dose Enerzair Breezhaler was in line with previous studies in the Phase III/IIIb PLATINUM clinical development program.

“This post hoc analysis supports the potential of high-dose IND/GLY/MF as an effective step-up treatment option to further reduce asthma exacerbations in patients with uncontrolled asthma,” said Kenneth Chapman, Professor of Medicine, University of Toronto. “These findings also complement the efficacy and safety data from the pivotal IRIDIUM study, which indicated the potential of high-dose IND/GLY/MF to improve lung function and reduce exacerbations compared with salmeterol xinafoate/fluticasone propionate (Sal/Flu), a LABA/ICS* standard-of-care.”

The analysis showed high-dose Enerzair Breezhaler (150/50/160 μg) significantly reduced the annualized rate of moderate-or-severe asthma exacerbations by 21% (p=0.026) and severe exacerbations by 31% (p=0.003) in asthma patients not adequately controlled on current inhaled therapies, compared with medium-dose (150/50/80 μg) over 52 weeks.

High-dose Enerzair Breezhaler also reduced the annualized rate of all exacerbations (mild, moderate and severe) by 14% (p=0.132) compared with medium-dose, but this finding was not statistically significant. Both doses tested presented with a favorable safety and tolerability profile.

*LABA; long-acting beta2-agonist, LAMA; long-acting muscarinic antagonist, ICS; inhaled corticosteroid.

About Uncontrolled Asthma
Asthma affects an estimated 358 million people worldwide and can cause a significant personal, health and financial burden when not adequately controlled4,5. Despite current therapy, over 40% of patients with asthma at Global Initiative for Asthma (GINA) Step 3, and over 45% at GINA Steps 4 and 5 remain uncontrolled6,7. Patients with uncontrolled asthma may downplay or underestimate the severity of their disease and are at a higher risk of exacerbation, hospitalization or death8–10. Barriers, such as less than optimal adherence, incorrect inhaler technique, treatment mismatch, safety issues with oral corticosteroids and ineligibility for biologics, have created an unmet medical need in asthma11–14.

About Enerzair® Breezhaler® in the EU
On July 7, 2020, Novartis announced European Commission (EC) approval of Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) 150/50/160 μg once-daily as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) and a high-dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year2. This formulation combines the bronchodilation of indacaterol acetate (a LABA) and glycopyrronium bromide (a LAMA) with mometasone furoate (ICS) in a precise once-daily formulation, delivered via the dose-confirming Breezhaler device. Glycopyrronium bromide certain use and formulation intellectual property were exclusively licensed to Novartis in April 2005 by Sosei Heptares and Vectura. Mometasone furoate is exclusively licensed to Novartis from a subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA, for use in IND/GLY/MF (worldwide excluding the US).

IND/GLY/MF will be administered via the dose-confirming Breezhaler device, which enables once-daily inhalation using a single inhaler. IND/GLY/MF is the first asthma treatment in the EU that can be prescribed together with a digital companion; the Propeller Health app and sensor custom-built for the Breezhaler device. The digital companion will provide patients with inhalation confirmation, medication reminders and access to objective data that can be shared with their physician in order to help them make better therapeutic decisions. The sensor for the Breezhaler device was developed by Propeller Health and is a CE marked medical device, designed and licensed to Novartis for use with the Breezhaler inhaler worldwide. The sensor includes a microchip, a microphone, Bluetooth capabilities, an antenna and a battery. The sensor does not alter the drug delivery characteristics of the Breezhaler inhaler itself but produces a recording of each administered dose. Based on the patient’s recorded medication usage, personalized content is presented within the app to help the patient better self-manage their asthma.

In keeping with the Novartis commitment to reduce the environmental impact of our asthma combinations, IND/GLY/MF will be available in the hydrofluoroalkane/chlorofluorocarbon (HFA/CFC)-free Breezhaler device. Novartis aims to drive sustainability and has set ambitious targets to minimize its impact on climate, waste and water, including targets to become carbon neutral in company operations by 2025.

About the IRIDIUM Study3
IRIDIUM was a Phase III, multicenter, randomized, double-blind, parallel-group study, designed to compare the efficacy and safety of IND/GLY/MF with IND/MF in patients with asthma.

The purpose of the study was to evaluate the efficacy and safety of two different doses of IND/GLY/MF (high: 150/50/160 μg and medium: 150/50/80 μg), versus two corresponding IND/MF doses (high: 150/320 μg and medium: 150/160 μg) in patients with uncontrolled asthma, as determined by pulmonary function testing and effects on asthma control.

All patients were required to be symptomatic at screening and to have one or more exacerbations in the previous year, despite being on treatment with medium- or high-stable doses of LABA/ICS. Approximately 3,092 male and female adult patients with asthma were randomized 1:1:1:1:1 (approximately 618 patients in each of the treatment groups) to receive one of the following treatments:

  • IND/GLY/MF 150/50/80 μg (once-daily)
  • IND/GLY/MF 150/50/160 μg (once-daily)
  • IND/MF 150/160 μg (once-daily)
  • IND/MF 150/320 μg (once-daily)
  • Sal/Flu 50/500 μg (twice-daily)             

The primary objective of this study was to demonstrate superiority of both high-dose IND/GLY/MF versus high-dose IND/MF and medium-dose IND/GLY/MF versus medium-dose IND/MF, all delivered once-daily, in improving trough FEV1 (volume of air that can be forced out in the first second of expiration approximately 24 hours post-administration of study drug) after 26 weeks of treatment in patients with asthma.

The key secondary objective was to demonstrate the superiority of both doses of IND/GLY/MF versus respective doses of IND/MF, in improving Asthma Control Questionnaire score after 26 weeks of treatment in patients with asthma.

Other secondary analyses included reduction of exacerbation rate, comparing high-dose IND/GLY/MF with high-dose IND/MF and medium-dose IND/GLY/MF with medium-dose IND/MF. Secondary analyses also included efficacy comparisons for both doses of IND/GLY/MF compared with Sal/Flu (50/500 μg).

Disclaimer
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “seek,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 140 nationalities work at Novartis around the world. Find out more at
https://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at https://twitter.com/novartisnews
For Novartis multimedia content, please visit https://www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

References
1.    Chapman KR, Kostikas K, Kerstjens H, et al. Reduction in asthma exacerbations with indacaterol/ glycopyrronium/ mometasone high-dose versus medium-dose: a post hoc analysis from the IRIDIUM study. e-Poster presented at the European Respiratory Society (ERS) Virtual Congress; 2020 Sept 7–9.
2.    European Medicines Agency. Enerzair Breezhaler. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/enerzair-breezhaler [Last accessed: August 2020].
3.    Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium-mometasone versus indacaterol-mometasone or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled Phase III study. Lancet Resp Med 2020. doi: 10.1016/S2213-2600(20)30190-9.
4.    GBD Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Resp Med 2017;5(9):691–706.
5.    Asthma and Allergy Foundation of America. My Life With Asthma Survey Overview. Available from: https://www.aafa.org/media/1684/my-life-with-asthma-in-2017-survey-findings-report.pdf [Last accessed: August 2020].
6.    Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43(2):343–373.
7.    Fang J, Busse WW, Marvel J, et al. Demographic, Clinical Characteristics and Control Status of Pediatric, Adolescent, and Adult Asthma Patients by GINA Step in a US Longitudinal Cohort. Am J Resp Crit Care Med 2018;197:A1903.
8.    Peters SP, Ferguson G, Deniz Y, Reisner C. Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100(7):1139–1151.
9.    Katsaounou P, Odemyr M, Spranger O, et al. Still Fighting for Breath: a patient survey of the challenges and impact of severe asthma. ERJ Open Res 2018;4(4):00076–2018.
10.  Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med 2014;24:14009.
11.  Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy 2018;11:193–204.
12.  Albers FC, Müllerová H, Gunsoy NB, et al. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. J Asthma 2018;55(2):152–160.
13.  Bourdin A, Halimi L, Vachier I, et al. Adherence in Severe Asthma. Clin Exp Allergy 2012;42(11):1566–1574.
14.  Global Initiative for Asthma (GINA). 2020 GINA pocket guide for asthma management and prevention. Available from: https://ginasthma.org/wp-content/uploads/2020/04/Main-pocket-guide_2020_04_03-final-wms.pdf [Last accessed: August 2020].

# # #

Novartis Media Relations
E-mail: media.relations@novartis.com

Peter Zuest
Novartis External Communications
+41 79 899 9812 (mobile)
peter.zuest@novartis.com



Eric Althoff
Novartis US External Communications
+1 646 438 4335
eric.althoff@novartis.com
Phil McNamara
Global Head, Respiratory Communications
+41 79 510 8756 (mobile)
phil.mcnamara@novartis.com

Novartis Investor Relations
Central investor relations line: +41 61 324 7944
E-mail: investor.relations@novartis.com

CentralNorth America
Samir Shah +41 61 324 7944 Sloan Simpson +1 862 778 5052
Thomas Hungerbuehler +41 61 324 8425
Isabella Zinck +41 61 324 7188


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

GOGL – Notice of Annual General Meeting 202120.4.2021 22:14:11 CEST | Press release

Golden Ocean Group Limited (the “Company”) announces that its 2021 Annual General Meeting will be held on May 26, 2021. A copy of the Notice of Annual General Meeting and associated information including the Company`s Consolidated Financial Statements on Form 20-F for 2020 can be found on our website at www.goldenocean.bm and in the links below. April 20, 2021 The Board of Directors Golden Ocean Group Limited Hamilton, Bermuda This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments GOGL - 2020 Form 20-FGOGL - Notice of Annual General Meeting 2021

RAPALA VMC CORPORATION ISSUES POSITIVE PROFIT WARNING AND UPGRADES ITS OUTLOOK FOR 2021: EXPECTS COMPARABLE OPERATING PROFIT TO INCREASE SIGNIFICANTLY FROM PRIOR YEAR20.4.2021 20:10:00 CEST | Press release

Rapala VMC Corporation Stock Exchange Release April 20, 2021 at 9:10 p.m. RAPALA VMC CORPORATION ISSUES POSITIVE PROFIT WARNING AND UPGRADES ITS OUTLOOK FOR 2021: EXPECTS COMPARABLE OPERATING PROFIT TO INCREASE SIGNIFICANTLY FROM PRIOR YEAR Rapala VMC Corporation’s outlook for 2021 has improved as a result of stronger than anticipated financial performance during the first three months of the year as well as upgraded positive business outlook for the remaining part of the year. The Group now expects full year 2021 comparable operating profit to increase significantly from the previous year. Key drivers behind the upgraded outlook are exceptionally strong winter sales, strong continued demand for fishing gear as it remains a popular COVID-safe activity globally as well as faster than expected strategy implementation. Uncertainties however remain for the rest of the year and the COVID-19 pandemic continues to pose some risks for the full-year performance. The pandemic can impact the oper

Korrigering till kallelse till Nexstim Abp:s bolagsstämma20.4.2021 20:00:00 CEST | Pressemelding

Företagsmeddelande,Helsingfors, 20.4.2021 kl.21.00 (EEST) Korrigering till kallelse till Nexstim Abp:s bolagsstämma Aktieägarna i bolaget har med en stämmokallelse av 15 april 2021 kallats till Nexstim Abp:s (NXTMH:HEX, NXTMS:STO) (”Nexstim” eller ”bolaget”) bolagsstämma som hålls 11 maj 2021 klockan 12.00 (EEST). Stämmokallelsen innehåller ett skrivfel enligt vilket den överföring av aktier till de mottagande aktieägarna som krävs för den slutliga ändringen av antalet aktier (efter minskningen) utförs och antecknas på värdeandelskontona troligen senast 17 maj i Sverige och 19 maj i Finland. Oaktat det ovannämnda utförs och antecknas överföringen på värdeandelskontona troligen senast 17 maj i Finland och 19 maj i Sverige. Punkt A.15. i kallelsen till extra bolagsstämman har således ändrats som följer (ändringarna i fet stil): Den överföring av aktier till de mottagande aktieägarna som krävs för den slutliga ändringen av antalet aktier (efter minskningen) utförs och antecknas på värdean

Correction to the Invitation to the Annual General Meeting of Nexstim Plc20.4.2021 20:00:00 CEST | Press release

Company announcement, Helsinki, 20.4.2021 at 9:00 pm (EEST) Correction to the Invitation to the Annual General Meeting of Nexstim Plc In accordance with the invitation to the Annual General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") dated 15 April 2021, the shareholders of the Company have been invited to the Annual General Meeting to be held on 11 May 2021 commencing at 12.00 (EEST). The invitation to the meeting of 15 April 2021 includes a writing error stating that transfers of shares from the Company to the Receiving Shareholders required for the final adjustments of their number of shares (after reduction) are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Sweden and 19th May 2021 in Finland. Notwithstanding the above-mentioned, the transfers of shares are expected to take place and be recorded in book-entry accounts at the latest on 17th May 2021 in Finland and 19th May 2021 in Sweden. Consequently, it w

MSAB publicerar årsredovisning för 202020.4.2021 20:00:00 CEST | Pressemelding

MSABs årsredovisning för 2020 finns nu tillgänglig på bolagets hemsida, www.msab.com/investerare/finansiella-rapporter/, samt bilagt detta pressmeddelande. Tryckt version kommer att finnas tillgänglig inom kort och kan beställas hos bolaget per telefon + 46 (0) 8 739 02 70 eller per e-post info@msab.com. I moderbolagets resultaträkning har en utdelning erhållits från ett av bolagets utländska dotterbolag om 5.5 MSEK, vilket ej var inkluderat i bolagets bokslutskommuniké. Frågor ställs till: Verkställande direktör Joel Bollö, tel. 08-739 02 70, e-mail: joel.bollo@msab.com Denna information är sådan som MSAB, 556244-3050, är skyldigt att offentliggöra enligt lagen (2007:528) om värdepappersmarknaden. Informationen lämnades, genom ovanstående kontaktpersons försorg, för offentliggörande den 20 april 2021 klockan 20:00 CEST. Om MSAB MSAB är världsledande inom kriminalteknik för att utvinna och analysera data i beslagtagna mobila enheter. Företaget utvecklar högkvalitativ och lättanvänd mju

Flex LNG - AGM Notice20.4.2021 20:00:00 CEST | Press release

Flex LNG Ltd. (the "Company") announces that its 2021 Annual General Meeting will be held on May 26, 2021. A copy of the Notice of Annual General Meeting and associated information including the Company’s Annual Report on Form 20-F can be found in the links below and on our website at www.flexlng.com. April 20, 2021 The Board of Directors Flex LNG Limited Hamilton, Bermuda This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act or the Continuing Obligations of Oslo Børs. Attachments FLEX LNG - 20F 20202021 AGM Notice _FLEX (signed)

Banque Profil de Gestion SA : Assemblée Générale du 20 avril 202120.4.2021 18:04:22 CEST | Press release

Communiqué de presse Banque Profil de Gestion SA : Assemblée Générale du 20 avril 2021 Genève, le 20 avril 2021 – Lors de l’Assemblée Générale Ordinaire de la Banque Profil de Gestion SA (SIX Swiss Exchange : BPDG) qui s’est tenue aujourd’hui à Genève, 64.02% des actionnaires étaient représentés. Les actionnaires ont pris les décisions suivantes : Le rapport annuel et les comptes au 31 décembre 2020 ont été approuvés ;La pleine décharge a été donnée aux administrateurs de BPDG pour leur gestion durant l’exercice 2020 ;La couverture de la perte statutaire de CHF 2'336'667 avec la réserve légale issue du bénéfice a été approuvée ;Le versement d’un dividende de CHF 8'000'000 prélevé sur les réserves, soit un montant approximatif de CHF 0.5544 par action a été approuvé ;Madame Geneviève Berclaz, Monsieur Mario Aragnetti Bellardi, Monsieur Fabio Candeli, Monsieur Fulvio Pelli et Monsieur Fréderic Binder ont été réélus individuellement en qualité d’administrateur pour une durée de fonction d